iShares China Large-Cap ETF vs Tilray Brands Inc — how do they compare? iShares China Large-Cap ETF trades at $33.91 (market cap $3.86B), while Tilray Brands Inc trades at $3.53 (market cap $530.54M). The key difference: iShares China Large-Cap ETF is far larger — about 7.3× Tilray Brands Inc's market cap, and iShares China Large-Cap ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Tilray Brands Inc for 31 Days on average.
| FXI | TLRY | |
|---|---|---|
Market Cap | $3.86B | $530.54M |
Volume | 16,323,837 | 9,099,075 |
52-Week High | $41.08 | $21.00 |
52-Week Low | $31.59 | $3.57 |
Typical Hold Time | 149 Days | 31 Days |
Sector | — | Health |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $33.42, down 1.04% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges and trade tensions, though it trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54. Recent geopolitical developments from the Trump-Xi summit and China's export dynamics create mixed sentiment.
The outlook remains cautious with technical indicators signaling selling pressure, while fundamental valuation appears attractive for risk-tolerant investors seeking China exposure. Key risks include ongoing U.S.-China tensions, China's industrial overcapacity, and weak domestic consumption that could limit upside potential despite the valuation discount.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →